1. Cancer

Cancer

Cancer is a neoplastic disease caused by uncontrolled division of abnormal cells in a part of the body and their subsequent local invasion and systematic metastasis to other parts of the body. Oncogenic mutations, genome instability and inflammation initiate and expedite the acquisition of several hallmarks by cancer cells such as sustaining unlimited growth, resisting cell death, inducing angiogenesis, activating invasion and metastasis, reprogramming cellular metabolism, and evading immune checkpoints. Our large repertoire of cancer related small molecules are designed to facilitate both basic research on cancer biology and developing new strategies to treat cancer.

Cancer Related Products (4674):

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-10219
    Rapamycin 53123-88-9 99.93%
    Rapamycin (Sirolimus; AY 22989) is a potent and specific mTOR inhibitor with an IC50 of 0.1 nM in HEK293 cells. Rapamycin binds to FKBP12 and specifically acts as an allosteric inhibitor of mTORC1. Rapamycin is an autophagy activator, an immunosuppressant.
    Rapamycin
  • HY-13259
    MG-132 133407-82-6 >98.0%
    MG-132 is a peptide aldehyde and a potent, reversible, and cell-permeable proteasome inhibitor with an IC50 of 100 nM, and effectively blocks the proteolytic activity of the 26S proteasome complex.
    MG-132
  • HY-19312
    3-Methyladenine 5142-23-4 99.84%
    3-Methyladenine is a PI3K inhibitor. 3-Methyladenine is a widely used inhibitor of autophagy via its inhibitory effect on class III PI3K.
    3-Methyladenine
  • HY-10108
    LY294002 154447-36-6 99.95%
    LY294002 is a broad-spectrum inhibitor of PI3K with IC50s of 0.5, 0.57, and 0.97 μM for PI3Kα, PI3Kδ and PI3Kβ, respectively. LY294002 also inhibits CK2 with an IC50 of 98 nM. LY294002 is a competitive DNA-PK inhibitorr that binds reversibly to the kinase domain of DNA-PK with an IC50 of 1.4 μM.
    LY294002
  • HY-16658
    Z-VAD(OMe)-FMK 187389-52-2 98.20%
    Z-VAD(OMe)-FMK is a cell-permeable and irreversible pan-caspase inhibitor.
    Z-VAD(OMe)-FMK
  • HY-10162
    Olaparib 763113-22-0 99.98%
    Olaparib (AZD2281;KU0059436) is a potent and oral PARP inhibitor with IC50s of 5 and 1 nM for PARP1 and PARP2, respectively.
    Olaparib
  • HY-17394
    Cisplatin 15663-27-1 >99.0%
    Cisplatin is a antineoplastic chemotherapy drug which works by cross-linking with DNA and causing DNA damage in cancer cells.
    Cisplatin
  • HY-17559
    Actinomycin D 50-76-0 99.58%
    Actinomycin D inhibits DNA repair with an IC50 of 0.42 μM.
    Actinomycin D
  • HY-15142
    Doxorubicin hydrochloride 25316-40-9 99.47%
    Doxorubicin hydrochloride is a cytotoxic anthracycline antibiotic for the treatment of multiple cancers. The possible mechanisms by which doxorubicin acts in the cancer cell are intercalation into DNA and disruption of topoisomerase-II-mediated DNA repair. Doxorubicin hydrochloride reduces basal phosphorylation of AMPK and its downstream target acetyl-CoA carboxylase.
    Doxorubicin hydrochloride
  • HY-13030
    (+)-JQ-1 1268524-70-4 99.90%
    (+)-JQ-1 is a potent, specific, and reversible BET bromodomain inhibitor, with IC50s of 77 and 33 nM for the first and second bromodomain (BRD4(1/2)). (+)-JQ-1 also activates autophagy.
    (+)-JQ-1
  • HY-13316
    Mitomycin C 50-07-7 99.45%
    Mitomycin C is an antitumor drug and antibiotic that shows extraordinary ability to inhibit DNA synthesis. Mitomycin C is a DNA cross-linking agent, which induces DNA damaging.
    Mitomycin C
  • HY-12041
    SP600125 129-56-6 98.82%
    SP600125 is a cell-permeable, reversible, and ATP-competitive JNK inhibitor with IC50s of 40, 40 and 90 nM for JNK1, JNK2 and JNK3, respectively.
    SP600125
  • HY-15531
    Venetoclax 1257044-40-8 99.95%
    Venetoclax (ABT-199; GDC-0199) is a highly potent, selective and orally bioavailable Bcl-2 inhibitor with a Ki of less than 0.01 nM.
    Venetoclax
  • HY-100558
    Bafilomycin A1 88899-55-2 >99.0%
    Bafilomycin A1, a macrolide antibiotic isolated from the Streptomyces species, is a specific inhibitor of vacuolar-type H+ ATPase (V-ATPase). Bafilomycin A1 inhibits autophagy.
    Bafilomycin A1
  • HY-10583
    Y-27632 dihydrochloride 129830-38-2 99.83%
    Y-27632 dihydrochloride is a cell-permeable, ATP-competitive inhibitor of ROCK-I and ROCK-II, with Kis of 220 and 300 nM, respectively. Y-27632 dihydrochloride primes human induced pluripotent stem cells (hIPSCs) to selectively differentiate towards mesendodermal lineage via epithelial-mesenchymal transition-like modulation.
    Y-27632 dihydrochloride
  • HY-B0015
    Paclitaxel 33069-62-4 99.97%
    Paclitaxel (Taxol), a naturally occurring antineoplastic agent, stabilizes tubulin polymerization, resulting in arrest at the G2/M phase of the cell cycle and apoptotic cell death.
    Paclitaxel
  • HY-17471A
    Metformin hydrochloride 1115-70-4 99.98%
    Metformin (hydrochloride) is an FDA approved first-line drug for the treatment of type 2 diabetes. Metformin decreases hepatic glucose production, mostly through a mild and transient inhibition of the mitochondrial respiratory-chain complex 1.
    Metformin hydrochloride
  • HY-10182
    CHIR-99021 252917-06-9 99.76%
    CHIR-99021 is a GSK-3α/β inhibitor with an IC50 of 10 and 6.7 nM, showing 500-fold selectivity over its closest homologs CDC2 and ERK2, as well as other protein kinases.
    CHIR-99021
  • HY-10071
    Y-27632 146986-50-7 99.73%
    Y-27632 is an ATP-competitive inhibitor of ROCK-I and ROCK-II, with Ki of 220 nM and 300 nM for ROCK-I and ROCK-II, respectively, which primes human induced pluripotent stem cells (hIPSCs) to selectively differentiate towards mesendodermal lineage via epithelial-mesenchymal transition-like modulation.
    Y-27632
  • HY-70002
    Enzalutamide 915087-33-1 99.71%
    Enzalutamide (MDV3100) is an androgen receptor (AR) antagonist with an IC50 of 36 nM in LNCaP prostate cells.
    Enzalutamide